PipelineReview.com. Biopharmaceutical News & Clinical Trials
PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial
Dec 21, 2024 · Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177 Lu-RAD202 in Breast and Gastric Cancers; The Phase 1 First-In-Human study is designed to assess the safety, tolerability & preliminary clinical activity of 177 Lu-RAD202 in individuals with HER2-positive metastatic solid tumors; Ten HER2-positive breast cancer patients previously dosed in a ...
Timberlyne Therapeutics Launches with a $180 Million Series A …
Jan 10, 2025 · Mountainfield Venture Partners, a biopharmaceutical company creation firm, partners with Keymed Biosciences to form Timberlyne Therapeutics, accessing global development and commercial rights outside of greater China for CM313
Marea Therapeutics Provides Update on Corporate Progress …
Jan 10, 2025 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 …
Jan 15, 2025 · The primary endpoint of 12-month Event Free Survival (EFS) for OST-HER2- treated patients (33.3%) was statistically significant (p= 0.0158) when compared with peer-reviewed comparable historical control (20%)
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as …
Dec 21, 2024 · BRAFTOVI in combination with cetuximab and mFOLFOX6 is the first and only combination regimen with targeted therapy approved for use as early as first-line for patients with metastatic colorectal cancer with a BRAFV600E mutation; Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the Phase 3 BREAKWATER trial
Arrowhead Pharmaceuticals Announces Acceptance of New Drug …
5 days ago · – The New Drug Application is based on positive results from the Phase 3 PALISADE study – People living with familial chylomicronemia syndrome have extremely high triglyceride levels and a substantially higher risk of developing acute pancreatitis and associated long-term complications, including poor quality of life
Duality Biologics and GSK Enter Exclusive Option Agreement for a …
Dec 4, 2024 · PRINCETON, NJ, USA I SHANGHAI and SUZHOU, China I December 3, 2024 I Duality Biologics (“DualityBio”), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjugate (ADC) therapeutics, today announced that it has entered into an exclusive option agreement with GSK for a potentially best-in-class ADC candidate, DB-1324.
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral …
JENA, Germany I December 20, 2024 I InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the first patient has been dosed in its Phase 2a basket study in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS), investigating the Company’s oral C5aR inhibitor, INF904.
Biomea Fusion Presents Preclinical Data Showing Icovamenib …
Oct 31, 2024 · Preclinical data from ex vivo human islet experiments showed that icovamenib (BMF-219) was able to enhance the activity of glucagon-like peptide-1 (GLP-1)-based therapies, potentially leading to increased insulin secretion and improved glycemic control in …